Terence A. Kelly
Amministratore Delegato presso Perception Neuroscience Holdings, Inc.
Posizioni attive di Terence A. Kelly
Società | Posizione | Inizio | Fine |
---|---|---|---|
Perception Neuroscience Holdings, Inc. | Amministratore Delegato | 01/11/2019 | - |
Presidente | 01/11/2019 | - | |
Perception Neuroscience, Inc.
Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Amministratore Delegato | - | - |
Storia della carriera di Terence A. Kelly
Precedenti posizioni note di Terence A. Kelly
Società | Posizione | Inizio | Fine |
---|---|---|---|
CARDAX, INC. | Direttore/Membro del Consiglio | 16/06/2014 | 01/08/2021 |
Independent Dir/Board Member | 16/06/2014 | 01/08/2021 | |
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Amministratore Delegato | 01/01/2011 | 01/01/2017 |
Presidente | 01/01/2011 | 01/01/2017 | |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | 01/01/1990 | 01/01/2009 |
Kelly Pharma Research Consulting LLC | Fondatore | - | - |
Cardax Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI. | Direttore/Membro del Consiglio | 17/06/2014 | - |
Formazione di Terence A. Kelly
Rensselaer Polytechnic Institute | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Posizioni
Chief Executive Officer | 3 |
Director/Board Member | 2 |
President | 2 |
Settori
Health Technology | 5 |
Consumer Services | 4 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CARDAX, INC. | Health Technology |
Aziende private | 6 |
---|---|
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Cardax Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI. | Health Technology |
Kelly Pharma Research Consulting LLC | |
Perception Neuroscience Holdings, Inc. | |
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Perception Neuroscience, Inc.
Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Health Services |
- Borsa valori
- Insiders
- Terence A. Kelly
- Esperienza